PuSH - Publication Server of Helmholtz Zentrum München: A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Day, J.W.* ; Ottaway, N.* ; Patterson, J.T.* ; Gelfanov, V.* ; Smiley, D.* ; Gidda, J.* ; Findeisen, H.M.* ; Bruemmer, D.* ; Drucker, D.J.* ; Chaudhary, N.* ; Holland, J.* ; Hembree, J.* ; Abplanalp, W.* ; Grant, E.* ; Ruehl, J.* ; Wilson, H.* ; Kirchner, H.* ; Lockie, S.H.* ; Hofmann, S.* ; Woods, S.C.* ; Nogueiras, R.* ; Pfluger, P.T. ; Perez-Tilve, D.* ; DiMarchi, R.* ; Tschöp, M.H.*

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

Nat. Chem. Biol. 5, 749-57 (2009)

DOI

PMC

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects. Selective chemical modification to glucagon resulted in a loss of specificity, with minimal change to inherent activity. The structural basis for the co-agonism appears to be a combination of local positional interactions and a change in secondary structure. Two co-agonist peptides differing from each other only in their level of glucagon receptor agonism were studied in rodent obesity models. Administration of PEGylated peptides once per week normalized adiposity and glucose tolerance in diet-induced obese mice. Reduction of body weight was achieved by a loss of body fat resulting from decreased food intake and increased energy expenditure. These preclinical studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat reduction can be substantially enhanced without any overt adverse effects.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

0.000

2.330

365

405